血小板病原体灭活技术的临床应用现状及前景展望

doi:10.3969/j.issn.1671-2587.2021.04.029

临床输血与检验 ›› 2021, Vol. 23 ›› Issue (4): 540-544.DOI: 10.3969/j.issn.1671-2587.2021.04.029

• 综述 • 上一篇

血小板病原体灭活技术的临床应用现状及前景展望

张永鹏, 洪缨

610041 成都市血液中心

收稿日期:2020-08-28 发布日期:2021-08-18
通讯作者: 洪缨,女,主任技师,硕士,主要从事血液采集、制备相关研究,（E-mail）56527663@qq.com。
作者简介:张永鹏（1973-）,男,四川广元人,主管技师,本科,主要从事血液供应相关研究,（E-mail）510119859@qq.com。

Received:2020-08-28 Published:2021-08-18

摘要/Abstract

摘要： 随着医疗技术的发展,治疗性和预防性血小板输注挽救了许多患者的生命。浓缩血小板（platelet concentrates, PCs）是一种重要的血液成分,但PCs通常室温储存,易被细菌污染。因此,PCs的安全性一直备受关注。病原体灭活（pathogen inactivation,PI）技术是一种通过加入或不加入光敏剂,经紫外光照射使病原体核酸失活,同时灭活淋巴细胞替代辐照,防止输血相关移植物抗宿主（transfusion associated graft verse host disease, TA-GVHD）的措施。就目前血液预警数据显示,尚未发现病原体灭活血小板（pathogen inactivation-platelet concentrates, PI-PCs）引起的败血症等其他输血不良反应,且与常规血小板输注无显著差异。PI技术对血小板使用也有一定程度影响,可能会加剧储存损伤,导致输后血小板计数增量校正值（corrected count increment, CCI）低于常规血小板,使血小板输注间隔时间缩短。本文就目前PI技术及临床应用作以下综述。

关键词: 浓缩血小板, 病原体灭活技术, 安全性, 有效性

中图分类号:

R457

张永鹏, 洪缨. 血小板病原体灭活技术的临床应用现状及前景展望[J]. 临床输血与检验, 2021, 23(4): 540-544.

参考文献

[1] WHITE S K,SCHMIDT R L,WALKER B S,et al.Bacterial contamination rate of platelet components by primary culture:a systematic review and meta-analysis[J].Transfusion,2020,60(5):986-996.
[2] HAASS K A,SAPIANO M R P,SAVINKINA A,et al.Transfusion-transmitted infections reported to the national healthcare safety network hemovigilance module[J].Transfus Med Rev,2019,33(2):84-91.
[3] Food and Drug Administration.Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion[EB/OL].https://www.fda.gov/media/119043/download.
[4] BENJAMIN R J,BRASCHLER T,WEINGAND T,et al.Hemovigilance monitoring of platelet septic reactions with effective bacterial protection systems[J].Transfusion,2017,57(12):2946-2957.
[5] EICKMANN M,GRAVEMANN U,HANDKE W,et al.Inactivation of three emerging viruses-severe acute respiratory syndrome coronavirus,Crimean-Congo haemorrhagic fever virus and Nipah virus- in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light[J].Vox Sang,2020,115(3):146-151.
[6] MCCULLOUGH J,ALTER H J,NESS P M.Interpretation of pathogen load in relationship to infectivity and pathogen reduction efficacy[J].Transfusion,2019,59(3):1132-1146.
[7] IRSCH J,LIN L.Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT blood system™[J].Transfus Med Hemother,2011,38(1):19-31.
[8] NUSSBAUMER W,ALLERSTORFER D,ALLERSDORFER D,et al.Prevention of transfusion of platelet components contaminated with low levels of bacteria: a comparison of bacteria culture and pathogen inactivation methods[J].Transfusion,2007,47(7):1125-1133.
[9] GIRARD Y A,SANTA MARIA F,LANTERI M C.Inactivation of yellow fever virus with amotosalen and ultraviolet A light pathogen-reduction technology[J].Transfusion,2020,60(3):622-627.
[10] GOODRICH R P,EDRICH R A,LI J Z,et al.The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends[J].Transfus Apher Sci,2006,35(1): 5-17.
[11] Jocić M, Trkuljić M, Jovičić D,et al.Mirasol PRT system inactivation efficacy evaluated in platelet concentrates by bacteria-contamination model[J].Vojnosanit Pregl,2011,68(12):1041-1046.
[12] GOODRICH R P,GILMOUR D,HOVENGA N,et al.A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns[J].Transfusion,2009,49(6):1205-1216.
[13] KEIL S D,BENGRINE A,BOWEN R,et al.Inactivation of viruses in platelet and plasma products using a riboflavin-and-UV-based photochemical treatment[J].Transfusion,2015,55(7):1736-1744.
[14] PIOTROWSKI D,PRZYBYLSKA-BALUTA Z,JIMENEZ-MARCO T,et al.Passive haemovigilance of blood components treated with a riboflavin-based pathogen reduction technology[J].Trasfusione Del Sangue,2018,16(4):348-351.
[15] SEGHATCHIAN J,TOLKSDORF F.Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system-an update[J].Transfus Apher Sci,2012,46(2): 221-229.
[16] GRAVEMANN U,HANDKE W,MÜLLER T H,et al.Bacterial inactivation of platelet concentrates with the THERAFLEX UV-Platelets pathogen inactivation system[J].Transfusion,2019,59(4):1324-1332.
[17] FADDY H M,FRYK J J,PROW N A,et al.Inactivation of dengue,chikungunya,and Ross River viruses in platelet concentrates after treatment with ultraviolet C light[J].Transfusion,2016,56(6 Pt 2):1548-1555.
[18] GOODRICH R P,CUSTER B,KEIL S,et al.Defining"adequate"pathogen reduction performance for transfused blood components[J].Transfusion,2010,50(8): 1827-1837.
[19] CARDIGAN R,TURNER C,HARRISON P.Current methods of assessing platelet function: relevance to transfusion medicine[J].Vox Sang,2005,88(3):153-163.
[20] GARBAN F,GUYARD A,LABUSSIÈRE H,et al.Comparison of the hemostatic efficacy of pathogen-reduced platelets vs untreated platelets in patients with thrombocytopenia and malignant hematologic diseases: a randomized clinical trial[J].JAMA Oncol,2018,4(4):468-475.
[21] BASHIR S,COOKSON P,WILTSHIRE M,et al.Pathogen inactivation of platelets using ultraviolet C light: effect on in vitro function and recovery and survival of platelets[J].Transfusion,2013,53(5):990-1000.
[22] JÓHANNSSON F,ÁRNASON N Á,LANDRÖ R,et al.Metabolomics study of platelet concentrates photochemically treated with amotosalen and UVA light for pathogen inactivation[J].Transfusion,2020,60(2):367-377.
[23] DIALLO I,BENMOUSSA A,LAUGIER J,et al.Platelet pathogen reduction technologies alter the MicroRNA profile of platelet-derived microparticles[J].Front Cardiovasc Med,2020,7:31.
[24] SALUNKHE V,DE CUYPER I M,PAPADOPOULOS P,et al.A comprehensive proteomics study on platelet concentrates:Platelet proteome,storage time and Mirasol pathogen reduction technology[J].Platelets,2019,30(3): 368-379.
[25] 刘燕,盖厦,张文静,等.维生素B₂光化学技术对单采血小板中白细胞和血小板源细胞因子释放的影响[J].中国实验血液学杂志,2017,25(4): 1212-1217.
[26] 吴红宜,单桂秋,施琳颖,等.短波紫外线病毒灭活技术对血小板体外功能影响的实验研究[J].中国输血杂志,2018,31(2):127-132.
[27] PRUDENT M,D'ALESSANDRO A,CAZENAVE J P,et al.Proteome changes in platelets after pathogen inactivation——an interlaboratory consensus[J].Transfus Med Rev,2014,28(2):72-83.
[28] MAGRON A,LAUGIER J,PROVOST P,et al.Pathogen reduction technologies: The pros and cons for platelet transfusion[J].Platelets,2018,29(1): 2-8.
[29] Mirasol Clinical Evaluation Study Group.A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology[J].Transfusion,2010,50(11):2362-2375.
[30] SCHULZ W L,MCPADDEN J,GEHRIE E A,et al.Blood utilization and transfusion reactions in pediatric patients transfused with conventional or pathogen reduced platelets[J].J Pediatr,2019,209:220-225.
[31] JACQUOT C,DELANEY M.Pathogen-inactivated blood products for pediatric patients: blood safety,patient safety,or both?[J].Transfusion,2018,58(9):2095-2101.
[32] ESTCOURT L J,MALOUF R,HOPEWELL S,et al.Pathogen-reduced platelets for the prevention of bleeding[J].Cochrane Database Syst Rev,2017,7: CD009072.
[33] BAHAR B,SCHULZ W L,GOKHALE A,et al.Blood utilisation and transfusion reactions in adult patients transfused with conventional or pathogen-reduced platelets[J].Br J Haematol,2020,188(3):465-472.
[34] JIMENEZ-MARCO T,GARCIA-RECIO M,GIRONA-LLOBERA E.Use and safety of riboflavin and UV light-treated platelet transfusions in children over a five-year period: focusing on neonates[J].Transfusion,2019,59(12):3580-3588.
[35] KNUTSON F,OSSELAER J,PIERELLI L,et al.A prospective,active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment[J].Vox Sang,2015,109(4): 343-352.
[36] MERTES P M,TACQUARD C,ANDREU G,et al.Hypersensitivity transfusion reactions to platelet concentrate: a retrospective analysis of the French hemovigilance network[J].Transfusion,2020,60(3): 507-512.
[37] PROWSE C V.Component pathogen inactivation: a critical review[J].Vox Sang,2013,104(3):183-199.
[38] STOLLA M.Pathogen reduction and HLA alloimmunization: more questions than answers[J].Transfusion,2019,59(3):1152-1155.
[39] PIERELLI L,VACCA M,ZINI G,et al.Emergency response of four transfusion centers during the last Chikungunya outbreak in Italy[J].Transfusion,2018,58(12):3027-3030.
[40] SANTA MARIA F,LAUGHHUNN A,LANTERI M C,et al.Inactivation of Zika virus in platelet components using amotosalen and ultraviolet A illumination[J].Transfusion,2017,57(8):2016-2025.

血小板病原体灭活技术的临床应用现状及前景展望

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 10

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	邸艳辉, 管行, 寇立舵, 白薇, 王新华. AIHA患者血型血清学特征及输注悬浮红细胞疗效分析[J]. 临床输血与检验, 2021, 23(4): 455-458.
[2]	黄佳丽, 刘正婷, 陈尚良, 周义文. 亚甲蓝光病毒灭活血浆的研究进展^*[J]. 临床输血与检验, 2021, 23(2): 268-272.
[3]	钟明璐, 黄慧瑛, 张旸, 王立, 汪传喜, 魏亚明. 储存式自体输血在脊柱外科手术中应用的疗效及安全性研究^*[J]. 临床输血与检验, 2021, 23(1): 68-71.
[4]	中国输血协会临床输血管理委员会. 气动管道系统传送血液制剂安全性评估要求^*[J]. 临床输血与检验, 2019, 21(1): 1-2.
[5]	刁荣华, 王泽蓉, 王世春, 黄红梅, 赵树铭, 范娅涵. 不同方式放置白膜制备浓缩血小板质量指标比较^*[J]. 临床输血与检验, 2019, 21(1): 24-27.
[6]	裴德翠, 郑金秀. 新鲜冰冻血浆使用合理性及有效性回顾性分析[J]. 临床输血与检验, 2019, 21(1): 44-47.
[7]	杨鹏,闻慧琴,卫玉芝,卞茂红,张循善. 血浆置换在临床危重疾病治疗中的安全性分析*[J]. 临床输血与检验, 2018, 20(3): 242-245.
[8]	王舒莹, 李晓明, 杨涛, 孙志强, 刘震岳, 王平. 不同模式汇集白膜层法制备浓缩血小板的临床应用[J]. 临床输血与检验, 2017, 19(2): 127-129.
[9]	史恩祥, 任爱玲. 血浆输注安全有效性研究进展[J]. 临床输血与检验, 2016, 18(3): 298-301.
[10]	高加良,雷宇,万浬科,王红,袁理. 汇集浓缩血小板滤除白细胞前后质量检测分析[J]. 临床输血与检验, 2016, 18(1): 71-74.